146 related articles for article (PubMed ID: 33637585)
1. Head-to-Head Comparison of
Suh M; Im HJ; Ryoo HG; Kang KW; Jeong JM; Prakash S; Ballal S; Yadav MP; Bal C; Jeong CW; Kwak C; Cheon GJ
J Nucl Med; 2021 Oct; 62(10):1457-1460. PubMed ID: 33637585
[No Abstract] [Full Text] [Related]
2. Phase I Clinical Trial of Prostate-Specific Membrane Antigen-Targeting
Suh M; Ryoo HG; Kang KW; Jeong JM; Jeong CW; Kwak C; Cheon GJ
Korean J Radiol; 2022 Sep; 23(9):911-920. PubMed ID: 35762185
[TBL] [Abstract][Full Text] [Related]
3. Early Injection of Furosemide Increases Detection Rate of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for
Uprimny C; Bayerschmidt S; Kroiss AS; Fritz J; Nilica B; Svirydenka H; Decristoforo C; von Guggenberg E; Horninger W; Virgolini IJ
J Nucl Med; 2021 Nov; 62(11):1550-1557. PubMed ID: 33712533
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the diagnostic utility of 99mTc-PSMA scintigraphy versus 68Ga-PSMA-11 PET/CT in the detection of metastatic prostate cancer and dosimetry analysis: a gamma-camera-based alternate prostate-specific membrane antigen imaging modality.
Singh B; Sharma S; Bansal P; Hooda M; Singh H; Parihar AS; Kumar A; Watts A; Mohan R; Singh SK
Nucl Med Commun; 2021 May; 42(5):482-489. PubMed ID: 33395191
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.
Prasad V; Steffen IG; Diederichs G; Makowski MR; Wust P; Brenner W
Mol Imaging Biol; 2016 Jun; 18(3):428-36. PubMed ID: 27038316
[TBL] [Abstract][Full Text] [Related]
6. Development of a Ga-68 labeled PET tracer with short linker for prostate-specific membrane antigen (PSMA) targeting.
Moon SH; Hong MK; Kim YJ; Lee YS; Lee DS; Chung JK; Jeong JM
Bioorg Med Chem; 2018 May; 26(9):2501-2507. PubMed ID: 29655611
[TBL] [Abstract][Full Text] [Related]
7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
8. Head-to-Head Comparison of
Han T; Quan Z; Wang M; Meng X; Zhang M; Ye J; Li G; Wang J; Kang F
Mol Pharm; 2023 Nov; 20(11):5646-5654. PubMed ID: 37862042
[TBL] [Abstract][Full Text] [Related]
9. Clinical Translation and First In-Human Use of [
Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
[TBL] [Abstract][Full Text] [Related]
10. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of
Hofman MS; Eu P; Jackson P; Hong E; Binns D; Iravani A; Murphy D; Mitchell C; Siva S; Hicks RJ; Young JD; Blower PJ; Mullen GE
J Nucl Med; 2018 Apr; 59(4):625-631. PubMed ID: 28986512
[No Abstract] [Full Text] [Related]
11. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.
Afshar-Oromieh A; Hetzheim H; Kratochwil C; Benesova M; Eder M; Neels OC; Eisenhut M; Kübler W; Holland-Letz T; Giesel FL; Mier W; Kopka K; Haberkorn U
J Nucl Med; 2015 Nov; 56(11):1697-705. PubMed ID: 26294298
[TBL] [Abstract][Full Text] [Related]
12. Examining Absorbed Doses of Indigenously Developed
Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
[No Abstract] [Full Text] [Related]
13. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
[TBL] [Abstract][Full Text] [Related]
14. Bone scintigraphy as a gatekeeper for the detection of bone metastases in patients with prostate cancer: comparison with Ga-68 PSMA PET/CT.
Caglar M; Tuncel M; Yildiz E; Karabulut E
Ann Nucl Med; 2020 Dec; 34(12):932-941. PubMed ID: 32975741
[TBL] [Abstract][Full Text] [Related]
15. The frequency of thyroid incidental findings and risk of malignancy detected by
Gossili F; Petersen LJ; Zacho HD
Hell J Nucl Med; 2020; 23(3):240-245. PubMed ID: 33306753
[TBL] [Abstract][Full Text] [Related]
16. Correlation of Lesional Uptake Parameters and Ratios with miPSMA Score and Estimating Normal Physiologic Concentration: An Exploratory Analysis in Metastatic Castration-Resistant Prostatic Carcinoma Patients with
Kalshetty A; Menon B; Rakshit S; Bhattacharjee A; Basu S
J Nucl Med Technol; 2021 Sep; 49(3):235-240. PubMed ID: 34244223
[TBL] [Abstract][Full Text] [Related]
17. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging.
Demirci E; Sahin OE; Ocak M; Akovali B; Nematyazar J; Kabasakal L
Nucl Med Commun; 2016 Nov; 37(11):1169-79. PubMed ID: 27333090
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.
Ray Banerjee S; Chen Z; Pullambhatla M; Lisok A; Chen J; Mease RC; Pomper MG
Bioconjug Chem; 2016 Jun; 27(6):1447-55. PubMed ID: 27076393
[TBL] [Abstract][Full Text] [Related]
19. A prospective intra-individual comparison of [
Lawal IO; Mokoala KMG; Mahapane J; Kleyhans J; Meckel M; Vorster M; Ebenhan T; Rösch F; Sathekge MM
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):134-142. PubMed ID: 32424485
[TBL] [Abstract][Full Text] [Related]
20. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]